FDA-Approved Drug Library

• A unique collection of 1960 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);
• Bioactivity and safety confirmed by pre-clinical research evidence and clinical trials;
• An effective tool for discovering new with old drugs and new drug target identification;
• Covers various research areas: oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc
• Structurally diverse, medicinally active, and cell permeable;
• Rich documentation with structure, target, IC50 value and biological activity description;
• NMR and HPLC/LCMS validated to ensure high purity.

High-Standard Entry Criteria

TargetMol’s FDA-Approved Drug Library is curated with stringent entry criteria to ensure that every compound in the collection is structurally well-defined and of high purity. Multiple analytical techniques—such as NMR, HPLC, and LCMS—are employed to verify compound integrity. Through a rigorous multi-step screening process, we exclude compounds with ambiguous structures (e.g., mixtures and polymers) and non-active agents such as sunscreens, contrast agents, and inorganic compounds. This helps reduce ineffective screening efforts and unnecessary resource consumption. This library includes only FDA-approved small molecule drugs. For compounds approved by other regulatory agencies (such as PMDA, EMA, and NMPA), please refer to our L1000 Approved Drug Library,L1020 EMA Approved Drug Library L1000 Approved Drug Library and L1020 EMA Approved Drug Library.

Significant Structural Diversity

TargetMol’s FDA-Approved Drug Library exhibits remarkable structural diversity, offering substantial advantages in drug discovery. Based on MACCS fingerprint analysis, the library can be categorized into 1,392 classes, effectively covering a broad chemical space. The library includes a wide variety of compounds, ranging from simple to highly complex chemical structures. This diversity provides a wealth of possibilities for identifying lead compounds with high affinity and specificity for target proteins, significantly advancing drug innovation.

Diverse Compound Selection

TargetMol's FDA-Approved Drug Library features a highly diverse collection of compounds, both in terms of chemical structure and biological function. The library includes a broad range of key signaling pathway modulators, such as kinase inhibitors, G protein-coupled receptor (GPCR) ligands, ion channel modulators, and epigenetic regulators. These compounds cover a wide array of disease areas including cancer, immunological disorders, neurological diseases, metabolic conditions, and infectious diseases. In addition, the FDA-approved drugs span multiple administration routes, including but not limited to oral, injectable, inhalation, and topical applications. This comprehensive chemical space enables researchers to explore novel therapeutic approaches and accelerate the discovery of innovative medicines.

Regular Updates to Compound Libraries

TargetMol ensures compound libraries stay at the forefront of science by regularly updating our database to include the latest approved and marketed drugs.

Flexible Packaging Options

TargetMol provides a variety of standard packaging sizes (such as 30 μL, 50 μL, 100 μL, 250 μL, and 1 mg), and offer customized packaging solutions tailored to specific needs.

Personalized Custom Services

TargetMol offers fully customized screening services, including the design and synthesis of compound libraries. Our highly flexible service is designed to efficiently meet the unique needs of scientists and researchers.

• Powder or pre-dissolved DMSO solutions in 96/384 well plate with optional 2D barcode
• Shipped with blue ice
• This compound library is provided at a concentration of 10 mM in DMSO. A small number of compounds may be provided in different solvents or concentrations due to solubility or stability requirements. Please refer to the specific product information for details.